Clinical Trial Detail

NCT ID NCT04381650
Title A Safety and Efficacy Study of TAK-981 Plus Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Takeda
Indications

cervical squamous cell carcinoma

cervical adenocarcinoma

cervical adenosquamous carcinoma

colorectal cancer

lung non-squamous non-small cell carcinoma

Therapies

Pembrolizumab + TAK-981

Age Groups: adult senior

No variant requirements are available.